PDCD1 and neoplasm: found that combining immunotherapy (specifically nivolumab, a PD-1 inhibitor) with programmed exercise post-injection (aerobic and resistance training, 8 weeks) did not exhibit any additional effect on the inhibition of tumor growth compared to immunotherapy alone (25).